Orforglipron

Orforglipron
Above: skeletal diagram
Below: 3D representation
Clinical data
Trade namesFoundayo
Other namesLY-3502970
AHFS/Drugs.comMonograph
MedlinePlusa626059
License data
Routes of
administration		Oral
Drug classAntidiabetic, GLP-1 receptor agonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Elimination half-life29–49 hours
Identifiers
  • 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC48H48F2N10O5
Molar mass882.974 g·mol−1
3D model (JSmol)
  • Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
  • InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
  • Key:USUWIEBBBWHKNI-KHIFEHGGSA-N

Orforglipron, sold under the brand name Foundayo, is a medication used for weight management. It is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.

Orforglipron was approved for medical use in the United States in April 2026. It was approved for use in the UK in August 2026.

Medical uses

Orforglipron is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Adverse effects

Safety and dosing trials showed that the incidence of adverse events in orforglipron-treated participants was 62–89%, mostly from gastrointestinal discomfort (44–70% with orforglipron, 18% with placebo); in patients experiencing adverse events, 96% had mild to moderate GI side effects, while approximately 4% had severe nausea or vomiting. The most common side effects of orforglipon noted in clinical trials were vomiting, diarrhea, nausea, upset stomach, and constipation.

Mechanism of action

Orforglipron is a small-molecule, partial GLP-1 receptor agonist affecting the activity of cyclic adenosine monophosphate (cAMP); its effects are similar to the actions of glucagon-like peptide-1 (GLP-1) for reducing food intake and lowering blood glucose levels.

Society and culture

In October 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Foundayo, intended for the treatment of type 2 diabetes and for weight management. The applicant for this medicinal product is Eli Lilly Nederland.

Names

Orforglipron is the international nonproprietary name.

Orforglipron is sold under the brand name Foundayo.

References

  1. 1 2 "Foundayo- orforglipron tablet, film coated". DailyMed. April 1, 2026. Retrieved August 1, 2026.
  2. 1 2 Kokkorakis M, Chakhtoura M, Rhayem C, et al. (January 2025). "Emerging pharmacotherapies for obesity: A systematic review". Pharmacological Reviews. 77 (1) 100002. doi:10.1124/pharmrev.123.001045. hdl:11370/466f1da9-f22c-4d9a-be24-2680d416ebf9. PMID 39952695.
  3. 1 2 3 4 "Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial" (Press release). Eli Lilly and Company. April 17, 2025. Retrieved April 18, 2025.
  4. ↑ "FDA Approves First New Molecular Entity Under National Priority Voucher Program". U.S. Food and Drug Administration (FDA) (Press release). April 1, 2026. Retrieved April 5, 2026.
  5. ↑ "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions" (Press release). Eli Lilly and Company. April 1, 2026. Retrieved April 5, 2026.
  6. ↑ "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes". GOV.UK. Retrieved August 24, 2026.
  7. 1 2 Frias JP, Hsia S, Eyde S, et al. (August 2023). "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study". Lancet. 402 (10400): 472–483. doi:10.1016/S0140-6736(23)01302-8. PMID 37369232.
  8. ↑ Rosenstock J, Hsia S, Nevarez Ruiz L, et al. (June 21, 2025). "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes". New England Journal of Medicine. 393 (11). doi:10.1056/NEJMoa2505669.
  9. 1 2 "Foundayo EPAR". European Medicines Agency (EMA). October 16, 2026. Retrieved October 18, 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. ↑ "New oral GLP-1 medicine for weight management and type 2 diabetes". European Medicines Agency (EMA). October 16, 2026. Retrieved October 18, 2026.
  11. ↑ World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl:10665/373341.